艾伯维 2026年季度报告

(Mark One)☒ QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from AbbVie Inc. (Exact name of registrant as specified in its charter) 1 North Waukegan RoadNorth Chicago,Illinois 60064-6400 Telephone:(847) 932-7900 Indicate by check mark whether the registrant (1)hasfiled all reports required to befiled by Section13 or 15(d)of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2)has been subject to suchfiling requirements Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reporting company, or anemerging growth company. See the definitions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reporting company,” and "emerging growth company"in Rule12b-2 of the Exchange Act. Accelerated FilerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Securities registered pursuant to Section 12(b) of the Act: AbbVie Inc. and SubsidiariesTable of Contents PARTI.FINANCIAL INFORMATION Item 1.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATAItem 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS PARTII. Item 1.LEGAL PROCEEDINGSItem 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS AbbVie Inc. and SubsidiariesCondensed Consolidated Statements of Earnings (unaudited) 2026 Form 10-Q| AbbVie Inc. and SubsidiariesNotes to Condensed Consolidated Financial Statements (unaudited) Note 1 Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidatedfinancial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to therulesand regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosuresnormally included in annualfinancial statements prepared in accordance with generally accepted accounting principles in the United States(GAAP) have been omitted. These unaudited interim condensed consolidatedfinancial statements should be read in conjunction with thecompany’s audited consolidatedfinancial statements and notes included in the company’s Annual Report on Form10-K for the year endedDecember 31, 2025. It is management’s opinion that thesefinancial statements include all normal and recurring adjustments necessary for a fair presentation of thecompany’sfinancial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of futureor annual results. Certain other reclassifications were made to conform the prior period interim condensed consolidatedfinancial statements tothe current period presentation. Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted ASU No. 2024-03 In November 2024, the Financial Accounting Standards Board (FASB) issuedAccounting Standards Update (ASU) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40). The standard requires further disaggregation of relevantexpense captions in a separate note to thefinancial statements. The standard is effective for AbbVie starting in annual periods in 2027 and Note 2 Supplemental Financial Information Depreciation expense was $188 million for the three months ended March 31, 2026 and $181 million for the three months ended March 31,2025. Note 3 Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participatingsecurities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods The following table summarizes the impact of the two-class method: Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have beenantidilutive. The number of common shares excluded was insignificant for all periods presented. Note 4Licensing, Acquisitions and Other Arrangements Acquisition of Nimble Ther